A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail

Opioid Use Disorder Clinical Trial

— SOMATICS FRI  

Official title:

A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02334215
• Other study ID #: 3U01DA013636
• Secondary ID: 3U01DA013636
• Status: Completed
• Phase: N/A
• Start date: December 15, 2014
• Est. completion date: May 2020

Study information

• Verified date: September 2020
• Source: Friends Research Institute, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine which of three approaches started in jail is more effective in treating opioid use disorder: (1) methadone treatment without counseling (termed interim methadone) coupled with case management (termed patient navigation); (2) interim methadone without patient navigation; (3) or an enhanced treatment as usual including opioid detoxification, overdose prevention and drug treatment information and referral.

Description:

This study is part of the NIDA "Studies of Medication for Addiction Treatment in Correctional Settings (SOMATICS)" U01 Collaborative. Our distinct NIH-funded study at Friends Research Institute has been aligned with two other jail-based opioid treatment studies conducted by researchers at New York University (NYU) and at University of California Los Angeles (UCLA). SOMATICS seeks to harmonize assessments and interventions across the three research centers (RCs) and the three independent studies in order to leverage power, sample size, and increase the generalizability of findings. Each of the RCs in the SOMATICS cooperative will conduct their own individual trial, sharing one study arm with another RC, and several core assessments across all sites. The SOMATICS collaborative will have a common Statistical Analysis Plan and Data and Safety Monitoring Plan (DSMP) including a single DSMB. The collaborative primary and secondary outcomes across all sites are listed below:

Collaborative Primary Outcome Measure:

1. DSM-5 Opioid Use Disorder Diagnosis during the 30 days prior to the 6 months post-release follow-up assessment: Measured by: modified World Mental Health Composite International Diagnostic Interview.

Collaborative Secondary Outcome Measures:

1. Illicit Opioid use: measured by urine drug testing results at 6 months post-release

2. Number of days incarcerated: Measured by self-report during the 6 months post-release.

3. HIV risk behavior: Measured by self-report (Drug Risk Assessment Battery [RAB] Needle Use score) at the 6-month post-release follow-up assessment.

4. Number of days of Opioids, Cocaine, Alcohol, Benzodiazepines, and/or IV Drug Use:

Measured by Time Line Follow Back at 6 months post-release follow-up (TLFB; NYU, UCLA) and ASI (FRI).

5. Non-opioid drug use (Cocaine, Amphetamines, and Benzodiazepines): measured by urine drug testing at 6 months post-release

6. Number of days in any drug abuse treatment: Measured by self-report at 6 months post-release.

7. Number of arrests: Measured by self-report data collected at 6 months post-release.

8. Craving scores (for NYU and UCLA sites only): Measured by self-report craving scale at 6 months post-release.

9. Non-lethal overdose (Yes/No): Measured by self-report during the 6 months post-release.

10. Lethal overdose (Yes/No): Measured by public records data reviewed at 6 months post-release.

11. WHO Quality of Life-BREF (WHOQOL-BREF) score: Measured by self-report at 6 months post-release.

12. Analyses of above self-same outcomes at 12 months follow-up.

13. Once the primary trial is complete, the site in Baltimore will collect longer-term outcome data at a 24-month follow-up point through funding from the Arnold Foundation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 225
• Est. completion date: May 2020
• Est. primary completion date: March 8, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1) Meets Diagnostic and Statistical Manual -5 (DSM-5) criteria for opioid use disorder; (2) detained for at least 48 hours; (3) receiving opioid withdrawal treatment (as-usual) through the Detention Center's medical providers; (4) able and willing to provide informed consent in English; (5) detained for a charge that, if found guilty, will result in a sentence of less than 1 year; (6) plan to reside in Baltimore upon release; (7) 18 years of age and older.

Exclusion Criteria:

• (1) enrolled in methadone or buprenorphine treatment in the community at the time of arrest; (2) having a medical (liver failure, congestive heart failure) or psychiatric condition (e.g., suicidal ideation, psychosis) that would make participation unsafe in the judgment of the medical staff or the PI; (3) pregnancy; (4) allergy to methadone; and, (5) requiring treatment for alcohol or sedative hypnotic withdrawal.

Related Conditions & MeSH terms

• Opioid Use Disorder

Intervention

Drug:
• Methadone
Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.

Behavioral:
• Patient Navigation
A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
• Enhanced Treatment as Usual (ETAU)
Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.

Locations

Country	Name	City	State
United States	Baltimore City Detention Center	Baltimore	Maryland

Sponsors (3)

Lead Sponsor	Collaborator
Friends Research Institute, Inc.	Laura and John Arnold Foundation, National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Predicted Probability Derived From the Generalized Linear Mixed Model of Opioid Urine Test Positive Results Over Time	Predicted probability derived from the generalized linear mixed model opioid positive urine tests (0= negative; 1- positive) for heroin, oxycodone, methadone, or buprenorphine -- excluding the latter two positives when they results from prescribed medications to treat opioid use disorder)	1, 3, 6, and 12 months post-release from incarceration
Primary	Predicted Probability Derived From the General Linear Mixed Model of Entry Into Treatment for Opioid Use Disorder on the Methadone Treatment Exposure Form	Predicted probability derived from the general linear mixed model of self-reported entry into treatment for opioid use disorder following release from incarceration and being in treatment 30 days post-release (0= no entry in treatment; 1= entry in treatment).	30 days post-release from incarceration
Secondary	Predicted Probability Derived From Generalized Linear Mixed Model of Meeting Opioid Use Disorder Criteria as Determined by the Modified Composite International Diagnostic Interview (CIDI)	Predicted probability derived from the Generalized Linear Mixed Model of meeting the Data and Statistical Manual - 5 criteria for Opioid Use Disorder in response to modified CIDI interview (0= does not meet criteria; 1= meets criteria).	one month period prior to the 3, 6, and 12 month post-release from incarceration
Secondary	Number of Participants With Arrests	Official data on participant arrests subsequent to release from index incarceration.	one year post-release from incarceration
Secondary	Drug Risk Score on the Risk Assessment Battery (RAB)	Drug Risk Scale Score on the Risk Assessment Battery. The scale's range goes from 0 to 22. Higher score represents greater frequency of drug risk behaviors	Baseline and 6, and 12 months post-release from incarceration
Secondary	Sex Risk Score on the Risk Assessment Battery (RAB)	Sex Risk Score on the Risk Assessment Battery (RAB). Higher scores represents greater risk. The score ranges from 0 to 18.	Baseline and 6, and 12 months post-release from incarceration
Secondary	Physical Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)	The score on the Physical Domain Scale of the World Health Organization Quality of Life Scale-BREF (WHOQOL-BREF). The scales range is from 0 to 100. The higher score represents better quality of life.	1, 3, 6, and 12 months post-incarceration
Secondary	Psychological Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)	Scale score on the Psychological Domain on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. The higher score represents a better quality of life.	1, 3, 6, and 12 months post-release from incarceration
Secondary	Social Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)	Social domain scale score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. The higher score represents a better quality of life.	1, 3, 6, and 12 month post-release from incarceration
Secondary	Environmental Domain Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)	Environmental domain score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. A higher score represents a better quality of life.	1, 3, 6, and 12 months post-release from incarceration
Secondary	Overall Quality of Life Score on the World Health Organization Quality of Life Scale (WHOQOL-BREF)	Self report quality of life as reported by participants following release from their index incarceration on a scale from 1 to 5. A higher score is a better outcome.	1, 3, 6, and 12 month post-release from incarceration
Secondary	Predicted Probability Derived From the Generalized Linear Mixed Model of Being Retained in Treatment for Opioid Use Disorder on the Methadone Treatment Exposure Form	Predicted Probability derived from the Generalized Linear Mixed of self-reported enrolled in treatment for Opioid Use Disorder at the time of the follow-up interview (0=not enrolled; 1=enrolled).	12 months post-release from incarceration
Secondary	Mean Number of Days of Criminal Activity in the Past 30 Days Reported by Participants on the Addiction Severity Index (ASI)	Mean number of days reported by participants of their criminal activity during the 30 days preceding the Addiction Severity Index interviews	1, 3, 6, and 12 months post-release from incarceration
Secondary	Mean Number of Days of Illicit Opioid Use Reported by Participants in the Past 30 Days	Mean number of participant self-reported days of heroin use in the 30 days preceding the interview on the Addiction Severity Index (ASI)	1, 3, 6, and 12 months post-release from incarceration
Secondary	Participant Self-reported Mean Number of Days of Cocaine Use in the Past 30 Days	Participant self-reported mean number of days of cocaine use in the 30 days preceding the interview on the Addiction Severity Index (ASI)	1, 3, 6, and 12 months post-release from incarceration
Secondary	Predicted Probability Derived From the Generalized Linear Mixed Model of Meeting Cocaine Use Disorder Criteria in the Past 30 Days	Predicted Probability Derived from the Generalized Linear Mixed Model meeting Data and Statistical Manual - 5 criteria for Cocaine Use Disorder on the modified Composite International Diagnostic Interview (CIDI) (0=Does not meet criteria; 1=meets criteria).	3, 6, and 12 months post-release from incarceration
Secondary	Days of Hospitalization (Health Care Utilization) on the Economic Form 90 (EF-90)	Mean number of days hospitalized during the 12 months post-release from incarceration	12 months post-release from incarceration
Secondary	Cost of Substance Abuse Services	Cost in US Dollars of substance abuse services on the modified Substance Abuse Services Cost Analysis Program	12 months post-release from incarceration